P23H Rhodopsin Mutant Swine Model of Reninitis Pigmentosa
P23H Rhodopsin Mutant Swine Model of Reninitis Pigmentosa
批准号:
8204540
负责人:
HENRY Jerrold KAPLAN
金额:
$18.59万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-12-01 至 2013-11-30
关键词:
AdultAgeAnimal ModelAreaArtificial InseminationBiomedical EngineeringBlindnessCellsCharacteristicsClinicalCommunitiesCongenital AbnormalityDataDisadvantagedDiseaseDisease ProgressionExhibitsExtinction (Psychology)EyeFamily suidaeFutureGeneticHaplotypesHeterogeneityHistologicHistologyHumanImageInbreedingInheritance PatternsInheritedLifeMethodsMiniature SwineMissouriModelingMolecular AbnormalityMorphologyMutationNuclearPeripheralPharmacologyPhenotypePhotographyPopulationPositioning AttributePrincipal InvestigatorResearch Project GrantsResourcesRetinalRetinal ConeRetinal DegenerationRetinitis PigmentosaRhodopsinSeveritiesSiteTherapeuticTherapeutic InterventionTimeTransgenesTransgenic OrganismsTranslational ResearchTranslationsUnited States National Institutes of HealthUniversitiesVisionVisualWestern WorldWorkbaseclinical phenotypegene therapyinnovationinsightlight microscopymalemanmutantneurotrophic factornovel therapeutic interventionnuclear transferoffspringphotoreceptor degenerationpreventprogramsreconstitutionrelating to nervous systemresearch studyretinal prosthesisretinal regenerationretinal rodssomatic cell nuclear transferstem cell therapytransmission processtreatment effect
中文摘要
描述(由申请人提供):视网膜变性是西方世界失明的主要原因,色素性视网膜炎(RP)是成人生活中遗传性视力丧失的最常见原因。尽管RP的遗传基础已经得到了很好的探索,但由于这组疾病的突变异质性,将这种见解转化为成功的基因治疗一直受到阻碍。除了基因治疗,我们和其他人正在利用干细胞治疗、视网膜假体、生物工程和药理学的最新进展探索替代治疗方法。总之,这些都为RP成功的神经重建带来了希望。在美国密苏里-哥伦比亚大学国家养猪资源研究中心,采用单细胞核移植的方法,用NIH cc单倍型携带突变体Pro23His (P23H)人视紫红质转基因,培育了6只雄性迷你猪。我们的初步数据表明,这些创始人表现出RP的电生理表型特征。由于P23H是人类最常见的常染色体显性突变,我们建议建立一个群体,并对这种新型光感受器变性迷你猪模型的三个独立转基因系进行表征。虽然在这个应用程序的时间框架之外,在不久的将来,它可以被我们和视觉界用于新的治疗干预。
英文摘要
DESCRIPTION (provided by applicant): Retinal degeneration is a leading cause of blindness in the Western world and retinitis pigmentosa (RP) is the most common cause of hereditary visual loss in adult life. Although the genetic basis of RP has been well explored, the translation of this insight into successful genetic therapy has been hindered because of the mutational heterogeneity that underlies this group of diseases. In addition to gene therapy, we and others are exploring alternative therapeutic approaches employing recent advances in stem cell therapy, as well as the retinal prosthesis, bioengineering and pharmacology. Together these hold the promise for successful neural reconstitution in RP. Using the method of single cell nuclear transfer, we produced six male miniature swine (mini-swine) on a NIH cc haplotype carrying a mutant Pro23His (P23H) human rhodopsin transgene at the National Swine Resource Research Center at the University of Missouri-Columbia. Our preliminary data show that these founders exhibited an electrophysiologic phenotype characteristic of RP. Since P23H is the most common autosomal dominant mutation responsible for RP in man, we propose to establish a colony and characterize three independent transgenic lines of this new mini-swine model of photoreceptor degeneration. While outside the time frame of this application, in the near future it can be used by us and the vision community for novel therapeutic interventions.
PUBLIC HEALTH RELEVANCE: Using the method of single cell nuclear transfer, we produced six male miniature swine (mini-swine) on a NIH cc haplotype carrying a mutant Pro23His (P23H) human rhodopsin transgene at the National Swine Resource Research Center at the University of Missouri-Columbia. Our preliminary data show that these founders exhibited an electrophysiologic phenotype characteristic of retinitis pigmentosa (RP). Since P23H is the most common autosomal dominant mutation responsible for RP in humans, we propose to establish a colony and characterize three independent transgenic lines of this new mini-swine model of photoreceptor degeneration for future therapeutic interventions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Exsomes derived from retinal astrocytes in the regulation of retinal vasculature
-
批准号:9040963
-
项目类别:
-
资助金额:$18.75万
-
财政年份:2015
-
负责人:HENRY Jerrold KAPLAN
-
依托单位:
P23H Rhodopsin Mutant Swine Model of Reninitis Pigmentosa
-
批准号:8047278
-
项目类别:
-
资助金额:$23.52万
-
财政年份:2010
-
负责人:HENRY Jerrold KAPLAN
-
依托单位:
Targeting drug-delivery nanoparticles to sites of inflammation
-
批准号:7109581
-
项目类别:
-
资助金额:$34.27万
-
财政年份:2006
-
负责人:HENRY Jerrold KAPLAN
-
依托单位:
Targeting drug delivery nanoparticles to sites of inflammation
-
批准号:7684130
-
项目类别:
-
资助金额:$29.8万
-
财政年份:2006
-
负责人:HENRY Jerrold KAPLAN
-
依托单位:
Targeting drug delivery nanoparticles to sites of inflammation
-
批准号:7538931
-
项目类别:
-
资助金额:$28.77万
-
财政年份:2006
-
负责人:HENRY Jerrold KAPLAN
-
依托单位:
Vision Research Infrastructure Development
-
批准号:7057290
-
项目类别:
-
资助金额:$18.06万
-
财政年份:2004
-
负责人:HENRY Jerrold KAPLAN
-
依托单位:
Vision Research Infrastructure Development
-
批准号:6796942
-
项目类别:
-
资助金额:$30.67万
-
财政年份:2004
-
负责人:HENRY Jerrold KAPLAN
-
依托单位:
Vision Research Infrastructure Development
-
批准号:7214701
-
项目类别:
-
资助金额:$18.38万
-
财政年份:2004
-
负责人:HENRY Jerrold KAPLAN
-
依托单位:
Vision Research Infrastructure Development
-
批准号:6889187
-
项目类别:
-
资助金额:$17.8万
-
财政年份:2004
-
负责人:HENRY Jerrold KAPLAN
-
依托单位:
Vision Research Infrastructure Development
-
批准号:7394953
-
项目类别:
-
资助金额:$18.67万
-
财政年份:2004
-
负责人:HENRY Jerrold KAPLAN
-
依托单位:
IN VIVO IMAGING IN AUTOIMMUNE UVEITIS
-
批准号:6474557
-
项目类别:
-
资助金额:$33.18万
-
财政年份:1999
-
负责人:HENRY Jerrold KAPLAN
-
依托单位:
IN VIVO IMAGING IN AUTOIMMUNE UVEITIS
-
批准号:6077646
-
项目类别:
-
资助金额:$54.6万
-
财政年份:1999
-
负责人:HENRY Jerrold KAPLAN
-
依托单位:
IN VIVO IMAGING IN AUTOIMMUNE UVEITIS
-
批准号:6179801
-
项目类别:
-
资助金额:$21.42万
-
财政年份:1999
-
负责人:HENRY Jerrold KAPLAN
-
依托单位:
IN VIVO IMAGING IN AUTOIMMUNE UVEITIS
-
批准号:6747845
-
项目类别:
-
资助金额:$54.6万
-
财政年份:1999
-
负责人:HENRY Jerrold KAPLAN
-
依托单位:
IN VIVO IMAGING IN AUTOIMMUNE UVEITIS
-
批准号:6384896
-
项目类别:
-
资助金额:$54.6万
-
财政年份:1999
-
负责人:HENRY Jerrold KAPLAN
-
依托单位:
IN VIVO IMAGING IN AUTOIMMUNE UVEITIS
-
批准号:6525157
-
项目类别:
-
资助金额:$54.6万
-
财政年份:1999
-
负责人:HENRY Jerrold KAPLAN
-
依托单位:
EXPERIMENTAL ACUTE ANTERIOR UVEITIS
-
批准号:2684561
-
项目类别:
-
资助金额:$23.1万
-
财政年份:1994
-
负责人:HENRY Jerrold KAPLAN
-
依托单位:
EXPERIMENTAL ACUTE ANTERIOR UVEITIS
-
批准号:2164474
-
项目类别:
-
资助金额:$20.27万
-
财政年份:1994
-
负责人:HENRY Jerrold KAPLAN
-
依托单位:
EXPERIMENTAL ACUTE ANTERIOR UVEITIS
-
批准号:2164475
-
项目类别:
-
资助金额:$21.29万
-
财政年份:1994
-
负责人:HENRY Jerrold KAPLAN
-
依托单位:
EXPERIMENTAL ACUTE ANTERIOR UVEITIS
-
批准号:2164473
-
项目类别:
-
资助金额:$20.1万
-
财政年份:1994
-
负责人:HENRY Jerrold KAPLAN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
-
批准号:82505677
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.00万元
-
批准年份:2025
-
负责人:吕雨霏
-
依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
-
批准号:82574874
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2025
-
负责人:刘天华
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位: